The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
